Twist Bioscience reported fiscal fourth quarter revenue of $57.3 million on Friday, up 51% from $38.0 million in the fiscal fourth quarter of 2021.
Among its recent commercial highlights, the company noted that it has collaborated with PacBio to develop an initial portfolio of off-the-shelf long-read gene panels, including a 50-gene pharmacogenomics panel and a near of 400 complex and medically relevant genes. Genoa. The company noted that it has also partnered with Illumina to provide expanded customer access to an exome target enrichment panel designed to advance disease research.
For the three months ended Sept. 30, the company’s fourth-quarter net loss attributable to common shareholders was $51.1 million, or $0.91 per share, compared with $41.2 million, or 0. $84 per share, for the same period of fiscal 2021.
For all of fiscal 2022, the company reported revenue of $203.6 million, up 54% from $132.3 million in fiscal 2021.
At the end of the quarter, the company had cash and cash equivalents of $378.7 million and short-term investments of $126.3 million.
For the full fiscal year 2023, Twist expects revenue of between $261 million and $269 million and a net loss of approximately $260 million.
By the end of trading on the Nasdaq on Friday, shares of Twist were down more than 2% at $24.81.
Comments are closed.